Panait Claudia, D'Amelio Patrizia
Department of Medicine, Service of Geriatric Medicine & Geriatric Rehabilitation, University of Lausanne Hospital (CHUV), Lausanne, 1011, Switzerland.
Riviera-Chablais Hospital (HRC), Geriatrics and Rehabilitation Clinic (CGR), Vevey, 1800, Switzerland.
Aging Clin Exp Res. 2025 Apr 12;37(1):123. doi: 10.1007/s40520-025-02973-1.
Osteoporosis is a critical public health issue, particularly in the "older" (those aged over 75) and "oldest old" population (those aged 85 and above), who are at a heightened risk for fractures and related complications. This article reviews current osteoporosis treatments tailored for these age groups, emphasizing the balance between efficacy and safety, while considering cost/benefit aspects. We discuss pharmacological therapies available nowadays and their respective benefits and risks in the old population, based on the available literature on the subject. Special attention is given to specific features of this age category, like challenges of polypharmacy, physiological changes associated with age, comorbidities and patient adherence. This paper highlights the need for individualised treatment plans that consider the patient's overall health status, life expectancy and quality of life and the importance of continued innovation and personalized care in managing osteoporosis especially among the "older" population.
骨质疏松症是一个关键的公共卫生问题,在“老年”(75岁以上)和“高龄老人”(85岁及以上)人群中尤为突出,他们发生骨折及相关并发症的风险更高。本文回顾了针对这些年龄组的当前骨质疏松症治疗方法,强调疗效与安全性之间的平衡,同时考虑成本效益方面。基于该主题的现有文献,我们讨论了目前可用的药物治疗方法及其在老年人群中的各自益处和风险。特别关注这一年龄段的特定特征,如多重用药的挑战、与年龄相关的生理变化、合并症和患者依从性。本文强调需要制定考虑患者整体健康状况、预期寿命和生活质量的个性化治疗方案,以及在管理骨质疏松症方面持续创新和个性化护理的重要性,尤其是在“老年”人群中。